Integer Holdings Revenue 2010-2022 | ITGR

Integer Holdings revenue from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Integer Holdings Annual Revenue
(Millions of US $)
2021 $1,221
2020 $1,073
2019 $1,258
2018 $1,215
2017 $1,136
2016 $1,076
2015 $800
2014 $688
2013 $664
2012 $646
2011 $569
2010 $533
2009 $522
Integer Holdings Quarterly Revenue
(Millions of US $)
2022-03-31 $311
2021-12-31 $313
2021-09-30 $306
2021-06-30 $312
2021-03-31 $290
2020-12-31 $269
2020-09-30 $236
2020-06-30 $240
2020-03-31 $328
2019-12-31 $326
2019-09-30 $304
2019-06-30 $314
2019-03-31 $315
2018-12-31 $303
2018-09-30 $305
2018-06-30 $314
2018-03-31 $292
2017-12-31 $224
2017-09-30 $286
2017-06-30 $281
2017-03-31 $345
2016-12-31 $48
2016-09-30 $347
2016-06-30 $348
2016-03-31 $332
2015-12-31 $318
2015-09-30 $147
2015-06-30 $175
2015-03-31 $161
2014-12-31 $170
2014-09-30 $172
2014-06-30 $172
2014-03-31 $174
2013-12-31 $177
2013-09-30 $168
2013-06-30 $171
2013-03-31 $148
2012-12-31 $159
2012-09-30 $161
2012-06-30 $167
2012-03-31 $159
2011-12-31 $142
2011-09-30 $132
2011-06-30 $147
2011-03-31 $149
2010-12-31 $133
2010-09-30 $127
2010-06-30 $141
2010-03-31 $132
2009-12-31 $126
2009-09-30 $121
2009-06-30 $135
2009-03-31 $140
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $2.383B $1.221B
Integer Holdings Corporation manufactures and develops medical devices and components primarily for original equipment manufacturers, which depend on it to design, develop and produce intellectual property protected medical device technologies. Integer Holdings operates through two segments: Medical Sales and Non-Medical Sales. Medical Sales has three sub-segments Advanced Surgical, Orthopedics and Portable Medical; Cardio and Vascular; and Cardiac Rhythm Management & Neuromodulation.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $214.627B 21.80
Edwards Lifesciences (EW) United States $60.552B 42.53
Alcon (ALC) Switzerland $35.080B 30.59
STERIS (STE) Ireland $21.113B 26.67
Fresenius Medical Care AG KGaA (FMS) Germany $14.716B 13.22
Teleflex (TFX) United States $11.964B 19.12
Globus Medical (GMED) United States $5.873B 29.30
Penumbra (PEN) United States $4.736B 299.29
Glaukos (GKOS) United States $2.256B 0.00
Nevro (NVRO) United States $1.608B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.313B 23.51
Paragon 28 (FNA) United States $1.281B 0.00
Artivion (AORT) United States $0.772B 83.52